Search Results - "Gadaleta, C D"

Refine Results
  1. 1

    Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development by Ranieri, G, Gadaleta-Caldarola, G, Goffredo, V, Patruno, R, Mangia, A, Rizzo, A, Sciorsci, R L, Gadaleta, C D

    Published in Current medicinal chemistry (01-03-2012)
    “…Angiogenesis and signaling through the RAS/RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade have been…”
    Get more information
    Journal Article
  2. 2

    mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma by Guarini, A, Minoia, C, Giannoccaro, M, Rana, A, Iacobazzi, A, Lapietra, A, Raimondi, A, Silvestris, N, Gadaleta, C D, Ranieri, G

    Published in Current medicinal chemistry (01-03-2012)
    “…Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) are available and there is a need for new compounds…”
    Get more information
    Journal Article
  3. 3

    VEGF concentration from plasma‐activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model by Patruno, R., Arpaia, N., Gadaleta, C.D., Passantino, L., Zizzo, N., Misino, A., Lucarelli, N.M., Catino, A., Valerio, P., Ribatti, D., Ranieri, G.

    Published in Journal of cellular and molecular medicine (01-03-2009)
    “…Canine cutaneous mast cell tumour (CMCT) is a common cutaneous tumour in dog, with a higher incidence than in human. CMCT is classified in three subgroups,…”
    Get full text
    Journal Article
  4. 4

    A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies by Ranieri, G, Gadaleta, C.D, Patruno, R, Zizzo, N, Daidone, M.G, Hansson, M.G, Paradiso, A, Ribatti, D

    Published in Critical reviews in oncology/hematology (01-10-2013)
    “…Abstract Murine cancer models have been extremely useful for analyzing the biology of pathways involved in cancer initiation, promotion, and progression…”
    Get full text
    Journal Article
  5. 5

    Chymase-positive Mast cells correlate with tumor angiogenesis: first report in pancreatic cancer patients by Laface, C, Laforgia, M, Zito, A F, Loisi, D, Zizzo, N, Tamma, R, Gadaleta, C D, Porcelli, M, Currò, G, Ammendola, M, Ranieri, G

    “…Mast cells (MCs) are known to be involved in several physiological and pathological processes in humans and animals. Recently, their potential role in tumor…”
    Get more information
    Journal Article
  6. 6

    A modified cell block technique for fine needle aspiration cytology by Zito, F A, Gadaleta, C D, Salvatore, C, Filotico, R, Labriola, A, Marzullo, A, Prete, F, Marzullo, F

    Published in Acta cytologica (01-01-1995)
    “…A modification of the cell block technique, useful in processing material obtained by fine needle aspiration (FNA), is described. Four hundred six aspirates,…”
    Get more information
    Journal Article
  7. 7

    TEMPORARY REMOVAL: PO-63: Edoxaban effect in a breast cancer patient with liver arterial infusion chemotherapy (LAIC) and both jugular vein and hepatic artery thrombosis: a unique clinical case by Fioretti, A M, Leopizzi, T, Porcelli, M, Fazio, V, Ranieri, G, Luzzi, G, Gadaleta, C D, Oliva, S

    Published in Thrombosis research (01-05-2022)
    “…The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Hypoxic stop-flow perfusion with mitomycin-C in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall by Gadaleta, C D, Catino, A, Ranieri, G, Armenise, F, Console, G, Mattioli, V

    “…13 patients affected by multifocal and/or large liver metastases from various solid tumors have been treated with stop-flow liver perfusion, to evaluate the…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients by RANIERI, Girolamo, AMMENDOLA, Michele, RIBATTI, Domenico, PATRUNO, Rosa, CELANO, Giuseppe, ALFREDO ZITO, Francesco, MONTEMURRO, Severino, RELLA, Addolorata, DI LECCE, Valentina, DAMIANO GADALETA, Cosmo, BATTISTA DE SARRO, Giovanni

    Published in International journal of oncology (01-07-2009)
    “…Literature data indicate that mast cells (MCs) are involved in tumor angiogenesis due to the release of several pro-angiogenetic factors among which tryptase,…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results by Izzo, F., Catino, A. M., Vogl, T. J., Middleton, M., Valle, J. W., Fiore, F., Gadaleta, C. D., Pirotta, R. M., Martignoni, M., Laffranchi, B.

    Published in Journal of clinical oncology (20-05-2009)
    “…Abstract only 4593 Background: Nemorubicin is a novel DNA-intercalator, mainly metabolized in liver by CYP3A4 enzyme and showing synergic antitumor activity…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19
  20. 20

    P2-05-03: Is Breast Cancer Tryptase a Novel Anti-Angiogenetic Molecular Target? by Ranieri, G, Gadaleta-Caldarola, G, Misino, A, Patruno, R, Goffredo, V, Di Lecce, V, Vinciarelli, G, Valerio, P, Zito, A, Gadaleta, CD

    Published in Cancer research (Chicago, Ill.) (15-12-2011)
    “…Abstract Tryptase, a serine protease stored and released from mast cells granules has been identified as a new non-classical angiogenetic factor. Tryptase is…”
    Get full text
    Journal Article